JP2019517512A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517512A5 JP2019517512A5 JP2018563110A JP2018563110A JP2019517512A5 JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5 JP 2018563110 A JP2018563110 A JP 2018563110A JP 2018563110 A JP2018563110 A JP 2018563110A JP 2019517512 A5 JP2019517512 A5 JP 2019517512A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- months
- ctla
- body weight
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 230000004075 alteration Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 210000004602 germ cell Anatomy 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 101150061338 mmr gene Proteins 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 102100034157 DNA mismatch repair protein Msh2 Human genes 0.000 claims 1
- 102100021147 DNA mismatch repair protein Msh6 Human genes 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001134036 Homo sapiens DNA mismatch repair protein Msh2 Proteins 0.000 claims 1
- 101000968658 Homo sapiens DNA mismatch repair protein Msh6 Proteins 0.000 claims 1
- 101000738901 Homo sapiens PMS1 protein homolog 1 Proteins 0.000 claims 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 1
- 229910015837 MSH2 Inorganic materials 0.000 claims 1
- 108010074346 Mismatch Repair Endonuclease PMS2 Proteins 0.000 claims 1
- 102100037480 Mismatch repair endonuclease PMS2 Human genes 0.000 claims 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 claims 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 1
- 102100037482 PMS1 protein homolog 1 Human genes 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 102000043321 human CTLA4 Human genes 0.000 claims 1
- 102000048362 human PDCD1 Human genes 0.000 claims 1
- 230000033607 mismatch repair Effects 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022155878A JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662345662P | 2016-06-03 | 2016-06-03 | |
| US62/345,662 | 2016-06-03 | ||
| PCT/US2017/035822 WO2017210637A1 (en) | 2016-06-03 | 2017-06-02 | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Division JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019517512A JP2019517512A (ja) | 2019-06-24 |
| JP2019517512A5 true JP2019517512A5 (enExample) | 2020-07-16 |
Family
ID=59078186
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018563110A Pending JP2019517512A (ja) | 2016-06-03 | 2017-06-02 | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022155878A Active JP7721494B2 (ja) | 2016-06-03 | 2022-09-29 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
| JP2025093572A Pending JP2025143276A (ja) | 2016-06-03 | 2025-06-04 | 結腸直腸癌を有する患者の処置における抗ｐｄ－１抗体の使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11332529B2 (enExample) |
| EP (2) | EP3988570A1 (enExample) |
| JP (3) | JP2019517512A (enExample) |
| KR (3) | KR20240134249A (enExample) |
| CN (1) | CN109476754A (enExample) |
| ES (1) | ES2897964T3 (enExample) |
| WO (1) | WO2017210637A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2873402C (en) * | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| AU2015346295A1 (en) | 2014-11-13 | 2017-05-25 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| KR102740444B1 (ko) * | 2015-04-17 | 2024-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| JP7014706B2 (ja) | 2015-07-13 | 2022-02-01 | サイトメックス セラピューティクス インコーポレイテッド | 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法 |
| UA124379C2 (uk) | 2015-08-11 | 2021-09-08 | Усі Байолоджікс Айрленд Лімітед | Нові антитіла проти білка pd-1 |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| WO2017210637A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| US12398209B2 (en) * | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| WO2020033283A1 (en) * | 2018-08-09 | 2020-02-13 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of programmed death receptor (pd-1) antibodies and vicriviroc |
| JP7470105B2 (ja) * | 2018-09-13 | 2024-04-17 | メルク・シャープ・アンド・ドーム・エルエルシー | 非マイクロサテライト高不安定性／ミスマッチ修復の良好な結腸直腸がんを処置するためのｐｄ－１アンタゴニストおよびｌａｇ３アンタゴニストの組み合わせ |
| JP2022527177A (ja) * | 2019-03-28 | 2022-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 腫瘍を処置する方法 |
| GB201912107D0 (en) * | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| CN110656179A (zh) * | 2019-10-29 | 2020-01-07 | 至本医疗科技（上海）有限公司 | 免疫敏感性预测的生物标志组成物及用途、试剂盒设备存储介质 |
| CN113995835A (zh) * | 2021-10-09 | 2022-02-01 | 山东新创生物科技有限公司 | 戈氏梭菌芽孢联合pd-1抗体的应用 |
| AU2023373665A1 (en) * | 2022-10-31 | 2025-04-10 | Agenus Inc. | Methods of treating colorectal cancer using an anti-ctla4 antibody |
| TWI898418B (zh) * | 2023-02-09 | 2025-09-21 | 安邦生技股份有限公司 | 用以治療大腸癌的藥學套組及其用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| EP1340819A1 (en) * | 2002-02-28 | 2003-09-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Microsatellite markers |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| CN1845991A (zh) * | 2003-08-29 | 2006-10-11 | 田中纪章 | 核酸扩增用引物以及利用该引物检查结肠癌的检查方法 |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| RS54271B1 (sr) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| NZ582150A (en) | 2007-06-18 | 2012-08-31 | Msd Oss Bv | Antibodies to human programmed death receptor pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| HRP20170908T1 (hr) | 2008-12-09 | 2017-09-22 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
| JP2013512251A (ja) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害 |
| PT2504364T (pt) | 2009-11-24 | 2017-11-14 | Medimmune Ltd | Agentes de ligação direcionados contra b7-h1 |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| FI20115709A0 (fi) | 2011-07-01 | 2011-07-01 | Helsingin Yliopisto | Menetelmä perinnöllisten syöpien diagnosointiin |
| RS61033B1 (sr) | 2011-11-28 | 2020-12-31 | Merck Patent Gmbh | Antitela na pd-l1 i njihova upotreba |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| HRP20210122T1 (hr) | 2013-05-02 | 2021-04-16 | Anaptysbio, Inc. | Protutijela usmjerena protiv programirane smrti-1 (pd-1) |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| SG11201601844TA (en) | 2013-09-13 | 2016-04-28 | Beigene Ltd | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| SG11201604738TA (en) | 2013-12-12 | 2016-07-28 | Shanghai Hengrui Pharm Co Ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| US20170175197A1 (en) | 2014-01-29 | 2017-06-22 | Caris Mpi, Inc. | Molecular profiling of immune modulators |
| AU2015346295A1 (en) | 2014-11-13 | 2017-05-25 | The Johns Hopkins University | Checkpoint blockade and microsatellite instability |
| CA2978942A1 (en) | 2015-03-13 | 2016-09-22 | Cytomx Therapeutics, Inc. | Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof |
| US10995140B2 (en) * | 2015-06-05 | 2021-05-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy |
| WO2017210637A1 (en) | 2016-06-03 | 2017-12-07 | Bristol-Myers Squibb Company | Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer |
| CN110505882A (zh) | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
-
2017
- 2017-06-02 WO PCT/US2017/035822 patent/WO2017210637A1/en not_active Ceased
- 2017-06-02 KR KR1020247029228A patent/KR20240134249A/ko active Pending
- 2017-06-02 JP JP2018563110A patent/JP2019517512A/ja active Pending
- 2017-06-02 ES ES17731359T patent/ES2897964T3/es active Active
- 2017-06-02 KR KR1020187038115A patent/KR102515509B1/ko active Active
- 2017-06-02 EP EP21197402.7A patent/EP3988570A1/en active Pending
- 2017-06-02 US US16/306,290 patent/US11332529B2/en active Active
- 2017-06-02 CN CN201780048328.2A patent/CN109476754A/zh active Pending
- 2017-06-02 EP EP17731359.0A patent/EP3464373B1/en not_active Revoked
- 2017-06-02 KR KR1020237010151A patent/KR102702675B1/ko active Active
-
2022
- 2022-04-19 US US17/724,399 patent/US20220356254A1/en not_active Abandoned
- 2022-09-29 JP JP2022155878A patent/JP7721494B2/ja active Active
-
2024
- 2024-07-29 US US18/787,822 patent/US20250026831A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093572A patent/JP2025143276A/ja active Pending